BackSinovac Biotech, Overview

Sinovac Biotech, Receivables

Latest receivables for SVA: $310M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$313.09M

Peer trimmed avg / median

Loading

Sinovac Biotech, Receivables History

Loading

Sinovac Biotech, vs. peers: Receivables Comparison

Loading

Sinovac Biotech, Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Sinovac Biotech, (SVA) FAQ

As of the most recent data (December 2025), SVA shows a receivables of $310M. Scroll down for historical charts and peer comparison views.

Tracking SVA's receivables over time shows whether Sinovac Biotech, is scaling, shrinking, or reshaping that part of the business. The current reading is $310M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Sinovac Biotech,'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $310M) with ownership activity and broader fundamentals.

Sinovac Biotech,'s receivables is $310M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.